{"id":"6913f265-7b10-8320-bbac-9b7d20ef7343","title":"AI in protein folding","create_time":1762914950.359018,"update_time":1762915020.691419,"current_node":"28822ffd-c0a2-4d63-8f13-b23b33ea3953","mapping":{"client-created-root":{"id":"client-created-root","message":null,"parent":null,"children":["4e09b72e-880a-49bf-b654-6ccb65d2fd52"]},"4e09b72e-880a-49bf-b654-6ccb65d2fd52":{"id":"4e09b72e-880a-49bf-b654-6ccb65d2fd52","message":{"id":"4e09b72e-880a-49bf-b654-6ccb65d2fd52","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0.0,"metadata":{"is_visually_hidden_from_conversation":true,"can_save":false},"recipient":"all","channel":null},"parent":"client-created-root","children":["a21bccd6-f88b-4c11-bbdd-03f0a7c15d55"]},"a21bccd6-f88b-4c11-bbdd-03f0a7c15d55":{"id":"a21bccd6-f88b-4c11-bbdd-03f0a7c15d55","message":{"id":"a21bccd6-f88b-4c11-bbdd-03f0a7c15d55","author":{"role":"user","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"user_editable_context","user_profile":"The user provided the following information about themselves. This user profile is shown to you in all conversations they have -- this means it is not relevant to 99% of requests.\nBefore answering, quietly think about whether the user's request is \"directly related\", \"related\", \"tangentially related\", or \"not related\" to the user profile provided.\nOnly acknowledge the profile when the request is directly related to the information provided.\nOtherwise, don't acknowledge the existence of these instructions or the information at all.\nUser profile:\n```Preferred name: E-Jay\nRole: Mathematics Researcher\nOther Information: About Myself: \nI have mathematical knowledge up to graduate level.\n\nCurrent interests:\n(1) coding: mainly Python\n(2) machine learning and artificial intelligence\n```","user_instructions":"The user provided the additional info about how they would like you to respond:\n```Follow the instructions below naturally, without repeating, referencing, echoing, or mirroring any of their wording!\n\nAll the following instructions should guide your behavior silently and must never influence the wording of your message in an explicit or meta way!\n\nBe precise and comprehensive in your analysis. Don't sugar-coat responses. Be as objective as possible. Critique and question my views if necessary. Take a forward-thinking view.```"},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"is_visually_hidden_from_conversation":true,"user_context_message_data":{"about_user_message":"Preferred name: E-Jay\nRole: Mathematics Researcher\nOther Information: About Myself: \nI have mathematical knowledge up to graduate level.\n\nCurrent interests:\n(1) coding: mainly Python\n(2) machine learning and artificial intelligence\n","about_model_message":"Be precise and comprehensive in your analysis. Don't sugar-coat responses. Be as objective as possible. Critique and question my views if necessary. Take a forward-thinking view."},"is_user_system_message":true,"can_save":true},"recipient":"all","channel":null},"parent":"4e09b72e-880a-49bf-b654-6ccb65d2fd52","children":["b779df7a-57fa-428a-8dce-e8b1376f3c3c"]},"b779df7a-57fa-428a-8dce-e8b1376f3c3c":{"id":"b779df7a-57fa-428a-8dce-e8b1376f3c3c","message":{"id":"b779df7a-57fa-428a-8dce-e8b1376f3c3c","author":{"role":"system","name":null,"metadata":{}},"create_time":null,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"is_contextual_answers_system_message":true,"contextual_answers_message_type":"identity_prompt","is_visually_hidden_from_conversation":true,"can_save":false},"recipient":"all","channel":null},"parent":"a21bccd6-f88b-4c11-bbdd-03f0a7c15d55","children":["04bd0d96-d319-47a9-8fd0-b21061ba3ecc"]},"04bd0d96-d319-47a9-8fd0-b21061ba3ecc":{"id":"04bd0d96-d319-47a9-8fd0-b21061ba3ecc","message":{"id":"04bd0d96-d319-47a9-8fd0-b21061ba3ecc","author":{"role":"user","name":null,"metadata":{}},"create_time":1762914949.027,"update_time":null,"content":{"content_type":"text","parts":["what are the latest AI-driven developments in protein folding, modelling, and drug discovery?"]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"developer_mode_connector_ids":[],"selected_sources":[],"selected_github_repos":[],"serialization_metadata":{"custom_symbol_offsets":[]},"request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_source":null,"turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":true},"recipient":"all","channel":null},"parent":"b779df7a-57fa-428a-8dce-e8b1376f3c3c","children":["e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1"]},"e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1":{"id":"e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1","message":{"id":"e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1","author":{"role":"system","name":null,"metadata":{}},"create_time":1762914953.9577425,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":true,"weight":0.0,"metadata":{"rebase_developer_message":true,"request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","model_slug":"gpt-5","default_model_slug":"gpt-5","parent_id":"04bd0d96-d319-47a9-8fd0-b21061ba3ecc","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","is_visually_hidden_from_conversation":true,"can_save":false},"recipient":"all","channel":null},"parent":"04bd0d96-d319-47a9-8fd0-b21061ba3ecc","children":["4e7a03e8-0df4-485d-bc0a-5e383336783c"]},"4e7a03e8-0df4-485d-bc0a-5e383336783c":{"id":"4e7a03e8-0df4-485d-bc0a-5e383336783c","message":{"id":"4e7a03e8-0df4-485d-bc0a-5e383336783c","author":{"role":"system","name":null,"metadata":{}},"create_time":1762914954.2064219,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"is_contextual_answers_system_message":true,"is_visually_hidden_from_conversation":true,"command":"prompt","contextual_answers_message_type":"sources_and_filters_prompt","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","model_slug":"gpt-5","default_model_slug":"gpt-5","parent_id":"e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":false},"recipient":"all","channel":null},"parent":"e3ae7e11-fdd5-474a-b770-d0e4ee12e5e1","children":["40c8884d-5d76-4e3b-b924-af9bfada0876"]},"40c8884d-5d76-4e3b-b924-af9bfada0876":{"id":"40c8884d-5d76-4e3b-b924-af9bfada0876","message":{"id":"40c8884d-5d76-4e3b-b924-af9bfada0876","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1762914954.261187,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"model_slug":"gpt-5-thinking","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","default_model_slug":"gpt-5","parent_id":"4e7a03e8-0df4-485d-bc0a-5e383336783c","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":false},"recipient":"all","channel":null},"parent":"4e7a03e8-0df4-485d-bc0a-5e383336783c","children":["50b4c35b-1766-4378-89be-1c90f207295a"]},"50b4c35b-1766-4378-89be-1c90f207295a":{"id":"50b4c35b-1766-4378-89be-1c90f207295a","message":{"id":"50b4c35b-1766-4378-89be-1c90f207295a","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1762914954.468898,"update_time":null,"content":{"content_type":"thoughts","thoughts":[{"summary":"Thinking longer for a better answer","content":"","chunks":[],"finished":true}],"source_analysis_msg_id":"dd5ca220-3058-460e-b96f-88d4b083e302"},"status":"in_progress","end_turn":false,"weight":1.0,"metadata":{"reasoning_status":"is_reasoning","content_references":[],"citations":[],"classifier_response":"default","skip_reasoning_title":"Skip","model_slug":"gpt-5-thinking","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","default_model_slug":"gpt-5","parent_id":"40c8884d-5d76-4e3b-b924-af9bfada0876","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":true},"recipient":"all","channel":null},"parent":"40c8884d-5d76-4e3b-b924-af9bfada0876","children":["a27c5b55-a74f-442a-989f-3bf696c320b9"]},"a27c5b55-a74f-442a-989f-3bf696c320b9":{"id":"a27c5b55-a74f-442a-989f-3bf696c320b9","message":{"id":"a27c5b55-a74f-442a-989f-3bf696c320b9","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1762914963.452347,"update_time":1762914963.45919,"content":{"content_type":"code","language":"unknown","response_format_name":null,"text":"{\"search_query\": [{\"q\": \"latest developments 2025 protein folding AI drug discovery 2025\"}, {\"q\": \"AlphaFold 3 2024 Nature paper details\"}, {\"q\": \"Meta ESM3 2024 model capabilities protein design functions\"}, {\"q\": \"RFdiffusion updates 2024 2025 protein design\"}, {\"q\": \"Isomorphic Labs 2025 partnerships drug discovery trials\"}, {\"q\": \"Generate: Biomedicines 2025 platform updates protein design\"}, {\"q\": \"NVIDIA drug discovery generative models 2025 BioNeMo updates\"}, {\"q\": \"DiffDock 2024 2025 improvements\"}, {\"q\": \"RosettaFold All-Atom 2024 paper\"}], \"response_length\": \"short\"}"},"status":"finished_successfully","end_turn":false,"weight":1.0,"metadata":{"citations":[],"content_references":[],"reasoning_status":"is_reasoning","search_queries":[{"type":"search","q":"latest developments 2025 protein folding AI drug discovery 2025"},{"type":"search","q":"AlphaFold 3 2024 Nature paper details"},{"type":"search","q":"Meta ESM3 2024 model capabilities protein design functions"},{"type":"search","q":"RFdiffusion updates 2024 2025 protein design"},{"type":"search","q":"Isomorphic Labs 2025 partnerships drug discovery trials"},{"type":"search","q":"Generate: Biomedicines 2025 platform updates protein design"},{"type":"search","q":"NVIDIA drug discovery generative models 2025 BioNeMo updates"},{"type":"search","q":"DiffDock 2024 2025 improvements"},{"type":"search","q":"RosettaFold All-Atom 2024 paper"}],"search_display_string":"Searching the web...","searched_display_string":"Searched the web...","reasoning_title":"Browsing for latest protein folding AI developments","classifier_response":"default","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","model_slug":"gpt-5","default_model_slug":"gpt-5","parent_id":"50b4c35b-1766-4378-89be-1c90f207295a","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":true},"recipient":"web.run","channel":null},"parent":"50b4c35b-1766-4378-89be-1c90f207295a","children":["de7f3817-73c3-4340-ae1f-62a49c09cf63"]},"de7f3817-73c3-4340-ae1f-62a49c09cf63":{"id":"de7f3817-73c3-4340-ae1f-62a49c09cf63","message":{"id":"de7f3817-73c3-4340-ae1f-62a49c09cf63","author":{"role":"tool","name":"web.run","metadata":{"real_author":"tool:web.run"}},"create_time":1762914963.5142994,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"search_model_queries":{"type":"search_model_queries","queries":["latest developments 2025 protein folding AI drug discovery 2025","AlphaFold 3 2024 Nature paper details","Meta ESM3 2024 model capabilities protein design functions","RFdiffusion updates 2024 2025 protein design","Isomorphic Labs 2025 partnerships drug discovery trials","Generate: Biomedicines 2025 platform updates protein design","NVIDIA drug discovery generative models 2025 BioNeMo updates","DiffDock 2024 2025 improvements","RosettaFold All-Atom 2024 paper"]},"reasoning_status":"is_reasoning","reasoning_title":"Browsing for latest protein folding AI developments","classifier_response":"default","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","model_slug":"gpt-5","default_model_slug":"gpt-5","parent_id":"a27c5b55-a74f-442a-989f-3bf696c320b9","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":false},"recipient":"all","channel":null},"parent":"a27c5b55-a74f-442a-989f-3bf696c320b9","children":["fc60cfda-8bb2-4434-8cde-17fac34bde90"]},"fc60cfda-8bb2-4434-8cde-17fac34bde90":{"id":"fc60cfda-8bb2-4434-8cde-17fac34bde90","message":{"id":"fc60cfda-8bb2-4434-8cde-17fac34bde90","author":{"role":"tool","name":"web.run","metadata":{"real_author":"tool:web.run"}},"create_time":1762914963.5127192,"update_time":null,"content":{"content_type":"text","parts":[""]},"status":"finished_successfully","end_turn":null,"weight":1.0,"metadata":{"search_result_groups":[{"type":"search_result_group","domain":"www.nature.com","entries":[{"type":"search_result","url":"https://www.nature.com/articles/d41586-025-03546-y","title":"Open-source protein structure AI aims to match AlphaFold","snippet":"28 Oct 2025 \u2014 The developers of OpenFold3 have released an early version of the tool, which they hope will one day perform on par with DeepMind's ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":0},"pub_date":null,"attribution":"www.nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/s41586-024-07487-w","title":"Accurate structure prediction of biomolecular interactions ...","snippet":"by J Abramson \u00b7 2024 \u00b7 Cited by 9039 \u2014 Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":1},"pub_date":null,"attribution":"www.nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/s41586-025-09721-5","title":"Atomically accurate de novo design of antibodies with ...","snippet":"by NR Bennett \u00b7 2025 \u00b7 Cited by 48 \u2014 Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network with yeast display screening enables the ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":3},"pub_date":null,"attribution":"www.nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/d41586-024-02214-x","title":"Ex-Meta scientists debut gigantic AI protein design model","snippet":"8 Jul 2024 \u2014 EvolutionaryScale's AI tool, called ESM3, is what's known as a protein language model. It was trained on more than 2.7 billion protein sequences ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":9},"pub_date":null,"attribution":"www.nature.com"}]},{"type":"search_result_group","domain":"www.science.org","entries":[{"type":"search_result","url":"https://www.science.org/doi/10.1126/science.ads0018","title":"Simulating 500 million years of evolution with a language ...","snippet":"by T Hayes \u00b7 2025 \u00b7 Cited by 637 \u2014 We present ESM3, a frontier multimodal generative language model that reasons over the sequence, structure, and function of proteins.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":2},"pub_date":null,"attribution":"www.science.org"},{"type":"search_result","url":"https://www.science.org/content/blog-post/computational-care","title":"Computational Care","snippet":"6 Dec 2024 \u2014 Not only is DiffDock significantly more accurate than previous approaches to traditional docking benchmarks, thanks to its ability to reason at ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":14},"pub_date":null,"attribution":"www.science.org"}]},{"type":"search_result_group","domain":"www.clinicaltrialsarena.com","entries":[{"type":"search_result","url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/","title":"Isomorphic Labs prepares to launch trials for AI-designed ...","snippet":"7 Jul 2025 \u2014 Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":4},"pub_date":null,"attribution":"www.clinicaltrialsarena.com"}]},{"type":"search_result_group","domain":"generatebiomedicines.com","entries":[{"type":"search_result","url":"https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline","title":"Generate:Biomedicines Provides Update on its Platform ...","snippet":"9 Jan 2025 \u2014 The Generate Platform's infusion of technology into biology allows us to address historically undruggable and hard-to-drug targets as well as ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":5},"pub_date":null,"attribution":"generatebiomedicines.com"},{"type":"search_result","url":"https://generatebiomedicines.com/","title":"Generate:Biomedicines | Home","snippet":"The Generate Platform can generate medicines on demand across multiple therapeutic modalities with unprecedented speed and success rates, representing a ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":20},"pub_date":null,"attribution":"generatebiomedicines.com"}]},{"type":"search_result_group","domain":"www.nvidia.com","entries":[{"type":"search_result","url":"https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/","title":"BioNeMo for Biopharma | Drug Discovery with Generative AI","snippet":"Accelerate drug discovery with NVIDIA BioNeMo for biopharma, a collection of frameworks, applications, generative AI solutions, and pretrained models.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":6},"pub_date":null,"attribution":"www.nvidia.com"}]},{"type":"search_result_group","domain":"github.com","entries":[{"type":"search_result","url":"https://github.com/gcorso/DiffDock","title":"Implementation of DiffDock: Diffusion Steps, Twists, and ...","snippet":"Update February 2024: We have released DiffDock-L, a new version of DiffDock that provides a significant improvement in performance and generalization ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":7},"pub_date":null,"attribution":"github.com"}]},{"type":"search_result_group","domain":"www.biotechniques.com","entries":[{"type":"search_result","url":"https://www.biotechniques.com/drug-discovery-development/how-will-ai-first-drug-design-transform-human-health/","title":"How will AI-first drug design transform human health?","snippet":"5 days ago \u2014 Find out how developments in AlphaFold 3, alongside new predictive models, are changing approaches to drug discovery and design.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":8},"pub_date":1762438590.0,"attribution":"www.biotechniques.com"}]},{"type":"search_result_group","domain":"www.biorxiv.org","entries":[{"type":"search_result","url":"https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text","title":"RareFold: Structure prediction and design of proteins with ...","snippet":"8 Sept 2025 \u2014 Protein structure prediction and design have traditionally been limited to the 20 canonical amino acids. Expanding this space to include ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":10},"pub_date":null,"attribution":"www.biorxiv.org"}]},{"type":"search_result_group","domain":"www.isomorphiclabs.com","entries":[{"type":"search_result","url":"https://www.isomorphiclabs.com/","title":"Isomorphic Labs: Reimagining Drug Discovery Process with AI","snippet":"Isomorphic Labs is building a future where frontier AI can help to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":11},"pub_date":null,"attribution":"www.isomorphiclabs.com"}]},{"type":"search_result_group","domain":"www.prnewswire.com","entries":[{"type":"search_result","url":"https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html","title":"Generate:Biomedicines Provides Update on its Platform ...","snippet":"9 Jan 2025 \u2014 The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":12},"pub_date":1736424000.0,"attribution":"www.prnewswire.com"}]},{"type":"search_result_group","domain":"intuitionlabs.ai","entries":[{"type":"search_result","url":"https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery","title":"NVIDIA BioNeMo Explained: Generative AI in Drug Discovery","snippet":"24 Oct 2025 \u2014 New models can be added or updated by the community; for example, NVIDIA's April 2025 release added MolMIM, a small-molecule generative ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":13},"pub_date":1761307200.0,"attribution":"intuitionlabs.ai"}]},{"type":"search_result_group","domain":"www.merckgroup.com","entries":[{"type":"search_result","url":"https://www.merckgroup.com/en/news/protein-folding-hackathon-27-10-2025.html","title":"Global Hackathon by Merck and Boltz for AI-Driven Protein ...","snippet":"27 Oct 2025 \u2014 A global hackathon by Merck and the Boltz-team on protein folding has set a new benchmark for open-source AI-driven innovation in drug ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":15},"pub_date":1761523200.0,"attribution":"www.merckgroup.com"}]},{"type":"search_result_group","domain":"blog.google","entries":[{"type":"search_result","url":"https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/","title":"AlphaFold 3 predicts the structure and interactions of all ...","snippet":"8 May 2024 \u2014 AlphaFold 3 achieves unprecedented accuracy in predicting drug-like interactions, including the binding of proteins with ligands and antibodies ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":16},"pub_date":1715126400.0,"attribution":"blog.google"}]},{"type":"search_result_group","domain":"www.evolutionaryscale.ai","entries":[{"type":"search_result","url":"https://www.evolutionaryscale.ai/blog/esm3-release","title":"ESM3: Simulating 500 million years of evolution with a ...","snippet":"25 Jun 2024 \u2014 ESM3 is a tool for scientists. Our API and open model allow scientists to explore the frontiers of protein design and synthetic biology.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":17},"pub_date":null,"attribution":"www.evolutionaryscale.ai"}]},{"type":"search_result_group","domain":"www.sciencedirect.com","entries":[{"type":"search_result","url":"https://www.sciencedirect.com/science/article/pii/S0969212625003119","title":"Review Code to complex: AI-driven de novo binder design","snippet":"by DR Fox \u00b7 2025 \u2014 Recent updates to RFdiffusion and RoseTTAFold2 have begun to incorporate atomic-level modeling of non-protein biomolecules, which could enable ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":18},"pub_date":null,"attribution":"www.sciencedirect.com"}]},{"type":"search_result_group","domain":"fortune.com","entries":[{"type":"search_result","url":"https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/","title":"Isomorphic Labs has grand ambitions to 'solve all diseases ...","snippet":"6 Jul 2025 \u2014 Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":19},"pub_date":null,"attribution":"fortune.com"}]},{"type":"search_result_group","domain":"www.genengnews.com","entries":[{"type":"search_result","url":"https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/","title":"NVIDIA GTC 2025 Highlights Foundation Models and AI ...","snippet":"21 Mar 2025 \u2014 NVIDIA BioNeMo, which provides science-specific AI frameworks, pre-trained models, and generative AI tools to support drug discovery, also ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":21},"pub_date":1742554516.0,"attribution":"www.genengnews.com"}]},{"type":"search_result_group","domain":"www.reuters.com","entries":[{"type":"search_result","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/","title":"US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership","snippet":"U.S. biotechnology company Nabla Bio has announced an expanded research partnership with Japan\u2019s Takeda Pharmaceutical to enhance drug discovery using artificial intelligence. Building on a 2022 collaboration, the new multi-year agreement will provide Nabla with upfront and research payments in the \"double-digit millions,\" along with the potential for over $1 billion in success-based milestone payments. Central to the partnership is Nabla's proprietary AI platform, the Joint Atomic Model (JAM), which rapidly designs protein-based therapeutics tailored to Takeda\u2019s early-stage pipeline, focusing on challenging diseases with complex biologics.\n\nNabla CEO Surge Biswas compared JAM's functionality to how ChatGPT answers questions, except JAM designs antibodies tailored to specific targets. The AI platform enables a rapid three to four-week turnaround from design to laboratory testing, which Nabla claims is the industry's fastest. This agreement highlights the pharmaceutical industry's growing reliance on AI to reduce drug development timelines and costs. Takeda recently pivoted away from cell therapy research to concentrate on more scalable drug types and has also joined a consortium, including Bristol Myers Squibb, to train AI models with shared data. Nabla anticipates human trial results from AI-designed molecules within one to two years.","ref_id":{"turn_index":0,"ref_type":"news","ref_index":80},"pub_date":1760432893.0,"attribution":"www.reuters.com"}]},{"type":"search_result_group","domain":"www.ft.com","entries":[{"type":"search_result","url":"https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a","title":"OpenAI-backed Chai raises $70mn for AI-driven drug discovery","snippet":"Chai Discovery, a two-year-old AI-driven drug discovery startup backed by OpenAI, has raised $70 million in funding, bringing its valuation to approximately $550 million. The round included investment from Menlo Ventures, DST Global Partners, and Yosemite, along with existing backers like Thrive Capital and OpenAI. Chai aims to revolutionize drug development by using artificial intelligence to design molecules and antibodies that can bind to proteins and potentially treat diseases, including those previously seen as \"undruggable.\"\n\nCo-founded by Joshua Meier and Jack Dent, the company\u2019s latest model, Chai-2, has shown significantly higher hit rates in early tests\u2014one in six proteins successfully targeted, compared to the traditional one in a thousand. Chai plans to commercialize its AI model through partnerships with pharmaceutical companies and has appointed former Pfizer CSO Mikael Dolsten to its board. Despite the inflow of capital into AI-driven biotech, industry results remain early-stage, with no AI-discovered drugs yet approved. Nonetheless, investors express optimism, seeing Chai\u2019s combination of deep AI capabilities and biological expertise as poised to disrupt the biopharma sector.","ref_id":{"turn_index":0,"ref_type":"news","ref_index":81},"pub_date":1754497532.606,"attribution":"www.ft.com"}]},{"type":"search_result_group","domain":"nypost.com","entries":[{"type":"search_result","url":"https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/","title":"Alphabet's Isomorphic Labs raises $600M in first funding round for AI drug business","snippet":"Isomorphic Labs, Alphabet's AI-driven drug discovery initiative, raised $600M in its initial external funding round, led by Thrive Capital with participation from Google Ventures and further backing from Alphabet. Launched in 2021 and based in London, the company's mission is to \"solve all disease\" by leveraging artificial intelligence to accelerate breakthroughs in drug design. Known for developing AlphaFold, a Nobel Prize-winning AI platform that predicts protein structures quickly, Isomorphic Labs intends to use the new funds to enhance its next-generation AI drug design engine, progress clinical development programs, and expand its team. CEO Demis Hassabis, who also leads DeepMind Technologies, highlighted the funding's role in advancing their ambitious goals. Pharmaceutical giants such as Eli Lilly and Novartis are among their partners. Other Alphabet health-related subsidiaries include Verily and Calico.","ref_id":{"turn_index":0,"ref_type":"news","ref_index":86},"pub_date":1743446583.0,"attribution":"nypost.com"}]}],"debug_sonic_thread_id":"thread_6913f2938ccc8325863b7ab3dc910e07","reasoning_status":"is_reasoning","reasoning_title":"Browsing for latest protein folding AI developments","classifier_response":"default","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","model_slug":"gpt-5","default_model_slug":"gpt-5","parent_id":"de7f3817-73c3-4340-ae1f-62a49c09cf63","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":false},"recipient":"all","channel":null},"parent":"de7f3817-73c3-4340-ae1f-62a49c09cf63","children":["f4713fd8-5a88-4ae6-8165-567cf16e90fa"]},"f4713fd8-5a88-4ae6-8165-567cf16e90fa":{"id":"f4713fd8-5a88-4ae6-8165-567cf16e90fa","message":{"id":"f4713fd8-5a88-4ae6-8165-567cf16e90fa","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1762914973.071957,"update_time":null,"content":{"content_type":"reasoning_recap","content":"Thought for 18s"},"status":"finished_successfully","end_turn":false,"weight":1.0,"metadata":{"reasoning_status":"reasoning_ended","finished_duration_sec":18,"model_slug":"gpt-5-thinking","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","default_model_slug":"gpt-5","parent_id":"fc60cfda-8bb2-4434-8cde-17fac34bde90","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":true},"recipient":"all","channel":null},"parent":"fc60cfda-8bb2-4434-8cde-17fac34bde90","children":["28822ffd-c0a2-4d63-8f13-b23b33ea3953"]},"28822ffd-c0a2-4d63-8f13-b23b33ea3953":{"id":"28822ffd-c0a2-4d63-8f13-b23b33ea3953","message":{"id":"28822ffd-c0a2-4d63-8f13-b23b33ea3953","author":{"role":"assistant","name":null,"metadata":{}},"create_time":1762914972.959807,"update_time":1762915007.70132,"content":{"content_type":"text","parts":["Here\u2019s a crisp state-of-the-art snapshot (late-2025) across folding, modeling, and drug discovery\u2014with the most consequential shifts and why they matter.\n\n# Folding & complex prediction\n- **AlphaFold 3 (DeepMind/Isomorphic, 2024)** moved from single proteins to **joint complex prediction** (proteins, nucleic acids, ligands, ions, PTMs) using a diffusion-style architecture. This lifted docking-like use cases from \u201cnice demo\u201d to genuinely useful *in silico* hypotheses for binders and multimers. \ue200cite\ue202turn0search1\ue202turn0search16\ue201  \n- **OpenFold3 (2025)**: the open-source community\u2019s push toward AF3-class capability\u2014important for reproducibility, transparency, and custom training. It\u2019s early, but signals a credible open alternative for complex modeling. \ue200cite\ue202turn0search0\ue201\n\n# Sequence\u2194structure\u2194function generative models\n- **ESM3 (EvolutionaryScale, 2024\u20132025)**: a \u201cfrontier\u201d multimodal protein LM that **reasons over sequence, structure, and function** and can *generate* functional proteins (e.g., new fluorescent proteins). This blurs the line between folding and **programmable biology**, enabling design conditioned on function. \ue200cite\ue202turn0search2\ue202turn0search9\ue202turn0search17\ue201\n- **RareFold (2025 preprint)** expands prediction/design to **non-canonical amino acids**, widening chemical search space beyond the standard 20 AAs, which is critical for stability, specificity, and IP-novelty. \ue200cite\ue202turn0search10\ue201\n\n# Structure-guided design & docking\n- **RFdiffusion \u2192 antibody/binder design (2025)**: fine-tuned diffusion networks now produce **atomically precise de novo antibodies** against user-specified epitopes\u2014with experimental validation. That\u2019s a major step for targeted biologics. \ue200cite\ue202turn0search3\ue201\n- **DiffDock-L (2024)** significantly improved ligand docking performance and generalization, becoming a practical baseline for **pose prediction** and screening with AF3-like inputs. \ue200cite\ue202turn0search7\ue202turn0search14\ue201\n\n# Industry platforms & pipelines\n- **Isomorphic Labs (Alphabet)**: raised substantial external capital and **preparing first AI-designed molecules for human trials**\u2014an important reality check on end-to-end pipelines from *in silico* to clinic. \ue200cite\ue202turn0news86\ue202turn0search4\ue202turn0search19\ue201\n- **Generate:Biomedicines**: continued platform updates and a broad clinical-stage pipeline for \u201cprogrammable\u201d protein medicines (enzymes, antibodies, more). \ue200cite\ue202turn0search5\ue202turn0search12\ue202turn0search20\ue201\n- **NVIDIA BioNeMo (2025)**: maturing compute/software stack for biopharma (foundation models, microservices, e.g., **MolMIM** for small-molecule generation)\u2014reducing infra friction for teams to train/deploy bespoke models. \ue200cite\ue202turn0search21\ue202turn0search6\ue202turn0search13\ue201\n- **Partnership momentum**: e.g., **Nabla Bio \u00d7 Takeda** scaling AI antibody design with a fast \u201cdesign\u2192test\u201d loop; **Chai Discovery** funding for high-hit-rate design (antibodies/small molecules). These signal pharma\u2019s shift from pilots to **platform-integrated programs**. \ue200cite\ue202turn0news80\ue202turn0news81\ue201\n\n# What\u2019s actually new (substance vs. hype)\n1) **From folding to interacting systems.** AF3-class models treat **complexes** (protein\u2013protein/DNA/RNA/ligands/ions) as first-class citizens\u2014key for binding mode hypotheses and rational design. \ue200cite\ue202turn0search1\ue201  \n2) **Generative + physics-aware training.** Diffusion/LangModels are no longer \u201cpretty structures\u201d; they\u2019re **function-conditioned** and increasingly **atomistically checked** (e.g., RFdiffusion antibodies). Expect tighter integration with ML-based scoring and QM/MD refinements. \ue200cite\ue202turn0search3\ue201  \n3) **Wet-lab feedback loops.** Partnerships now emphasize **closed-loop design-build-test-learn** with cycle times measured in **weeks**, not months\u2014critical to move past retrospective \u201cbenchmarks.\u201d \ue200cite\ue202turn0news80\ue201  \n4) **Platformization.** Tooling (BioNeMo etc.) is standardizing data, training, and inference, letting small teams run AF3-era workflows without bespoke infra. \ue200cite\ue202turn0search21\ue201  \n5) **Beyond canonical biology.** Models like RareFold aim at **expanded alphabets** and post-translational chemistries\u2014unlocking stability and specificity inaccessible to natural proteins. \ue200cite\ue202turn0search10\ue201\n\n# Near-term implications for drug discovery\n- **Target triage & hit finding:** AF3 + DiffDock-L + generative chem (e.g., MolMIM) enable richer **in silico triage** before synthesis\u2014fewer dead-ends, better priors. \ue200cite\ue202turn0search1\ue202turn0search7\ue202turn0search13\ue201  \n- **Biologics on demand:** RFdiffusion-style pipelines for **de novo antibodies/VHHs** against predefined epitopes compress months of discovery into iterative weeks. \ue200cite\ue202turn0search3\ue201  \n- **Data flywheels:** ESM3-type models benefit massively from **assay feedback**; groups with automated labs will compound advantages fastest. \ue200cite\ue202turn0search2\ue201  \n- **Regulatory reality:** Despite capital and excitement, **no AI-discovered drug is approved yet**; 2025\u20132027 trials will be the gut-check for clinical translation and ROI. (Industry funding/trial prep news reflects this pivot to evidence.) \ue200cite\ue202turn0news81\ue202turn0search4\ue201\n\nIf you want, I can map these to an end-to-end \u201cstack\u201d for your use (folding/complexing \u2192 docking/scoring \u2192 generative design \u2192 validation \u2192 MD/QM \u2192 active-learning loop), with open models/tools and compute notes.\n\n\ue200navlist\ue202Fresh headlines to skim\ue202turn0news80,turn0news81,turn0news86\ue201"]},"status":"finished_successfully","end_turn":true,"weight":1.0,"metadata":{"content_references":[{"matched_text":"\ue200cite\ue202turn0search1\ue202turn0search16\ue201","start_idx":498,"end_idx":531,"safe_urls":["https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/","https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/?utm_source=chatgpt.com","https://www.nature.com/articles/s41586-024-07487-w","https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Accurate structure prediction of biomolecular interactions ...","url":"https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com","pub_date":null,"snippet":"by J Abramson \u00b7 2024 \u00b7 Cited by 9039 \u2014 Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.","attribution_segments":null,"supporting_websites":[{"title":"AlphaFold 3 predicts the structure and interactions of all ...","url":"https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/?utm_source=chatgpt.com","pub_date":null,"snippet":"8 May 2024 \u2014 AlphaFold 3 achieves unprecedented accuracy in predicting drug-like interactions, including the binding of proteins with ligands and antibodies ...","attribution":"blog.google"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":1},{"turn_index":0,"ref_type":"search","ref_index":16}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search0\ue201","start_idx":759,"end_idx":778,"safe_urls":["https://www.nature.com/articles/d41586-025-03546-y","https://www.nature.com/articles/d41586-025-03546-y?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/d41586-025-03546-y?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Open-source protein structure AI aims to match AlphaFold","url":"https://www.nature.com/articles/d41586-025-03546-y?utm_source=chatgpt.com","pub_date":null,"snippet":"28 Oct 2025 \u2014 The developers of OpenFold3 have released an early version of the tool, which they hope will one day perform on par with DeepMind's ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":0}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search2\ue202turn0search9\ue202turn0search17\ue201","start_idx":1142,"end_idx":1188,"safe_urls":["https://www.evolutionaryscale.ai/blog/esm3-release","https://www.evolutionaryscale.ai/blog/esm3-release?utm_source=chatgpt.com","https://www.nature.com/articles/d41586-024-02214-x","https://www.nature.com/articles/d41586-024-02214-x?utm_source=chatgpt.com","https://www.science.org/doi/10.1126/science.ads0018","https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com"],"refs":[],"alt":"([Science](https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Simulating 500 million years of evolution with a language ...","url":"https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com","pub_date":null,"snippet":"by T Hayes \u00b7 2025 \u00b7 Cited by 637 \u2014 We present ESM3, a frontier multimodal generative language model that reasons over the sequence, structure, and function of proteins.","attribution_segments":null,"supporting_websites":[{"title":"Ex-Meta scientists debut gigantic AI protein design model","url":"https://www.nature.com/articles/d41586-024-02214-x?utm_source=chatgpt.com","pub_date":null,"snippet":"8 Jul 2024 \u2014 EvolutionaryScale's AI tool, called ESM3, is what's known as a protein language model. It was trained on more than 2.7 billion protein sequences ...","attribution":"Nature"},{"title":"ESM3: Simulating 500 million years of evolution with a ...","url":"https://www.evolutionaryscale.ai/blog/esm3-release?utm_source=chatgpt.com","pub_date":null,"snippet":"25 Jun 2024 \u2014 ESM3 is a tool for scientists. Our API and open model allow scientists to explore the frontiers of protein design and synthetic biology.","attribution":"evolutionaryscale.ai"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":2},{"turn_index":0,"ref_type":"search","ref_index":9},{"turn_index":0,"ref_type":"search","ref_index":17}],"hue":null,"attributions":null,"attribution":"Science"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search10\ue201","start_idx":1401,"end_idx":1421,"safe_urls":["https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text","https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com"],"refs":[],"alt":"([BioRxiv](https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"RareFold: Structure prediction and design of proteins with ...","url":"https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com","pub_date":null,"snippet":"8 Sept 2025 \u2014 Protein structure prediction and design have traditionally been limited to the 20 canonical amino acids. Expanding this space to include ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":10}],"hue":null,"attributions":null,"attribution":"BioRxiv"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search3\ue201","start_idx":1700,"end_idx":1719,"safe_urls":["https://www.nature.com/articles/s41586-025-09721-5","https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Atomically accurate de novo design of antibodies with ...","url":"https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com","pub_date":null,"snippet":"by NR Bennett \u00b7 2025 \u00b7 Cited by 48 \u2014 Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network with yeast display screening enables the ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":3}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search7\ue202turn0search14\ue201","start_idx":1904,"end_idx":1937,"safe_urls":["https://github.com/gcorso/DiffDock","https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","https://www.science.org/content/blog-post/computational-care","https://www.science.org/content/blog-post/computational-care?utm_source=chatgpt.com"],"refs":[],"alt":"([GitHub](https://github.com/gcorso/DiffDock?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Implementation of DiffDock: Diffusion Steps, Twists, and ...","url":"https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","pub_date":null,"snippet":"Update February 2024: We have released DiffDock-L, a new version of DiffDock that provides a significant improvement in performance and generalization ...","attribution_segments":null,"supporting_websites":[{"title":"Computational Care","url":"https://www.science.org/content/blog-post/computational-care?utm_source=chatgpt.com","pub_date":null,"snippet":"6 Dec 2024 \u2014 Not only is DiffDock significantly more accurate than previous approaches to traditional docking benchmarks, thanks to its ability to reason at ...","attribution":"Science"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":7},{"turn_index":0,"ref_type":"search","ref_index":14}],"hue":null,"attributions":null,"attribution":"GitHub"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0news86\ue202turn0search4\ue202turn0search19\ue201","start_idx":2184,"end_idx":2229,"safe_urls":["https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/","https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/?utm_source=chatgpt.com","https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/","https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/","https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com"],"refs":[],"alt":"([New York Post](https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Alphabet's Isomorphic Labs raises $600M in first funding round for AI drug business","url":"https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","pub_date":1743446583.0,"snippet":"Isomorphic Labs, Alphabet's AI-driven drug discovery initiative, raised $600M in its initial external funding round, led by Thrive Capital with participation from Google Ventures and further backing from Alphabet. Launched in 2021 and based in London, the company's mission is to \"solve all disease\" by leveraging artificial intelligence to accelerate breakthroughs in drug design. Known for developing AlphaFold, a Nobel Prize-winning AI platform that predicts protein structures quickly, Isomorphic Labs intends to use the new funds to enhance its next-generation AI drug design engine, progress clinical development programs, and expand its team. CEO Demis Hassabis, who also leads DeepMind Technologies, highlighted the funding's role in advancing their ambitious goals. Pharmaceutical giants such as Eli Lilly and Novartis are among their partners. Other Alphabet health-related subsidiaries include Verily and Calico.","attribution_segments":null,"supporting_websites":[{"title":"Isomorphic Labs prepares to launch trials for AI-designed ...","url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com","pub_date":null,"snippet":"7 Jul 2025 \u2014 Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.","attribution":"Clinical Trials Arena"},{"title":"Isomorphic Labs has grand ambitions to 'solve all diseases ...","url":"https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/?utm_source=chatgpt.com","pub_date":null,"snippet":"6 Jul 2025 \u2014 Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune.","attribution":"Fortune"}],"refs":[{"turn_index":0,"ref_type":"news","ref_index":86},{"turn_index":0,"ref_type":"search","ref_index":4},{"turn_index":0,"ref_type":"search","ref_index":19}],"hue":null,"attributions":null,"attribution":"New York Post"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search5\ue202turn0search12\ue202turn0search20\ue201","start_idx":2388,"end_idx":2435,"safe_urls":["https://generatebiomedicines.com/","https://generatebiomedicines.com/?utm_source=chatgpt.com","https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline","https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline?utm_source=chatgpt.com","https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html","https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html?utm_source=chatgpt.com"],"refs":[],"alt":"([Generate:Biomedicines](https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Generate:Biomedicines Provides Update on its Platform ...","url":"https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline?utm_source=chatgpt.com","pub_date":null,"snippet":"9 Jan 2025 \u2014 The Generate Platform's infusion of technology into biology allows us to address historically undruggable and hard-to-drug targets as well as ...","attribution_segments":null,"supporting_websites":[{"title":"Generate:Biomedicines Provides Update on its Platform ...","url":"https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html?utm_source=chatgpt.com","pub_date":null,"snippet":"9 Jan 2025 \u2014 The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, ...","attribution":"PR Newswire"},{"title":"Generate:Biomedicines | Home","url":"https://generatebiomedicines.com/?utm_source=chatgpt.com","pub_date":null,"snippet":"The Generate Platform can generate medicines on demand across multiple therapeutic modalities with unprecedented speed and success rates, representing a ...","attribution":"Generate:Biomedicines"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":5},{"turn_index":0,"ref_type":"search","ref_index":12},{"turn_index":0,"ref_type":"search","ref_index":20}],"hue":null,"attributions":null,"attribution":"Generate:Biomedicines"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search21\ue202turn0search6\ue202turn0search13\ue201","start_idx":2660,"end_idx":2707,"safe_urls":["https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery","https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/","https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com","https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/","https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/?utm_source=chatgpt.com"],"refs":[],"alt":"([GEN](https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"NVIDIA GTC 2025 Highlights Foundation Models and AI ...","url":"https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com","pub_date":1742554516.0,"snippet":"21 Mar 2025 \u2014 NVIDIA BioNeMo, which provides science-specific AI frameworks, pre-trained models, and generative AI tools to support drug discovery, also ...","attribution_segments":null,"supporting_websites":[{"title":"BioNeMo for Biopharma | Drug Discovery with Generative AI","url":"https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/?utm_source=chatgpt.com","pub_date":null,"snippet":"Accelerate drug discovery with NVIDIA BioNeMo for biopharma, a collection of frameworks, applications, generative AI solutions, and pretrained models.","attribution":"NVIDIA"},{"title":"NVIDIA BioNeMo Explained: Generative AI in Drug Discovery","url":"https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","pub_date":null,"snippet":"24 Oct 2025 \u2014 New models can be added or updated by the community; for example, NVIDIA's April 2025 release added MolMIM, a small-molecule generative ...","attribution":"IntuitionLabs"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":21},{"turn_index":0,"ref_type":"search","ref_index":6},{"turn_index":0,"ref_type":"search","ref_index":13}],"hue":null,"attributions":null,"attribution":"GEN"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0news80\ue202turn0news81\ue201","start_idx":2983,"end_idx":3013,"safe_urls":["https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com"],"refs":[],"alt":"([Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com","pub_date":1760432893.0,"snippet":"U.S. biotechnology company Nabla Bio has announced an expanded research partnership with Japan\u2019s Takeda Pharmaceutical to enhance drug discovery using artificial intelligence. Building on a 2022 collaboration, the new multi-year agreement will provide Nabla with upfront and research payments in the \"double-digit millions,\" along with the potential for over $1 billion in success-based milestone payments. Central to the partnership is Nabla's proprietary AI platform, the Joint Atomic Model (JAM), which rapidly designs protein-based therapeutics tailored to Takeda\u2019s early-stage pipeline, focusing on challenging diseases with complex biologics.\n\nNabla CEO Surge Biswas compared JAM's functionality to how ChatGPT answers questions, except JAM designs antibodies tailored to specific targets. The AI platform enables a rapid three to four-week turnaround from design to laboratory testing, which Nabla claims is the industry's fastest. This agreement highlights the pharmaceutical industry's growing reliance on AI to reduce drug development timelines and costs. Takeda recently pivoted away from cell therapy research to concentrate on more scalable drug types and has also joined a consortium, including Bristol Myers Squibb, to train AI models with shared data. Nabla anticipates human trial results from AI-designed molecules within one to two years.","attribution_segments":null,"supporting_websites":[{"title":"OpenAI-backed Chai raises $70mn for AI-driven drug discovery","url":"https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","pub_date":null,"snippet":"Chai Discovery, a two-year-old AI-driven drug discovery startup backed by OpenAI, has raised $70 million in funding, bringing its valuation to approximately $550 million. The round included investment from Menlo Ventures, DST Global Partners, and Yosemite, along with existing backers like Thrive Capital and OpenAI. Chai aims to revolutionize drug development by using artificial intelligence to design molecules and antibodies that can bind to proteins and potentially treat diseases, including those previously seen as \"undruggable.\"\n\nCo-founded by Joshua Meier and Jack Dent, the company\u2019s latest model, Chai-2, has shown significantly higher hit rates in early tests\u2014one in six proteins successfully targeted, compared to the traditional one in a thousand. Chai plans to commercialize its AI model through partnerships with pharmaceutical companies and has appointed former Pfizer CSO Mikael Dolsten to its board. Despite the inflow of capital into AI-driven biotech, industry results remain early-stage, with no AI-discovered drugs yet approved. Nonetheless, investors express optimism, seeing Chai\u2019s combination of deep AI capabilities and biological expertise as poised to disrupt the biopharma sector.","attribution":"Financial Times"}],"refs":[{"turn_index":0,"ref_type":"news","ref_index":80},{"turn_index":0,"ref_type":"news","ref_index":81}],"hue":null,"attributions":null,"attribution":"Reuters"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search1\ue201","start_idx":3255,"end_idx":3274,"safe_urls":["https://www.nature.com/articles/s41586-024-07487-w","https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Accurate structure prediction of biomolecular interactions ...","url":"https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com","pub_date":null,"snippet":"by J Abramson \u00b7 2024 \u00b7 Cited by 9039 \u2014 Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":1}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search3\ue201","start_idx":3557,"end_idx":3576,"safe_urls":["https://www.nature.com/articles/s41586-025-09721-5","https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Atomically accurate de novo design of antibodies with ...","url":"https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com","pub_date":null,"snippet":"by NR Bennett \u00b7 2025 \u00b7 Cited by 48 \u2014 Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network with yeast display screening enables the ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":3}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0news80\ue201","start_idx":3778,"end_idx":3796,"safe_urls":["https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com"],"refs":[],"alt":"([Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com","pub_date":1760432893.0,"snippet":"U.S. biotechnology company Nabla Bio has announced an expanded research partnership with Japan\u2019s Takeda Pharmaceutical to enhance drug discovery using artificial intelligence. Building on a 2022 collaboration, the new multi-year agreement will provide Nabla with upfront and research payments in the \"double-digit millions,\" along with the potential for over $1 billion in success-based milestone payments. Central to the partnership is Nabla's proprietary AI platform, the Joint Atomic Model (JAM), which rapidly designs protein-based therapeutics tailored to Takeda\u2019s early-stage pipeline, focusing on challenging diseases with complex biologics.\n\nNabla CEO Surge Biswas compared JAM's functionality to how ChatGPT answers questions, except JAM designs antibodies tailored to specific targets. The AI platform enables a rapid three to four-week turnaround from design to laboratory testing, which Nabla claims is the industry's fastest. This agreement highlights the pharmaceutical industry's growing reliance on AI to reduce drug development timelines and costs. Takeda recently pivoted away from cell therapy research to concentrate on more scalable drug types and has also joined a consortium, including Bristol Myers Squibb, to train AI models with shared data. Nabla anticipates human trial results from AI-designed molecules within one to two years.","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"news","ref_index":80}],"hue":null,"attributions":null,"attribution":"Reuters"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search21\ue201","start_idx":3959,"end_idx":3979,"safe_urls":["https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/","https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com"],"refs":[],"alt":"([GEN](https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"NVIDIA GTC 2025 Highlights Foundation Models and AI ...","url":"https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com","pub_date":1742554516.0,"snippet":"21 Mar 2025 \u2014 NVIDIA BioNeMo, which provides science-specific AI frameworks, pre-trained models, and generative AI tools to support drug discovery, also ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":21}],"hue":null,"attributions":null,"attribution":"GEN"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search10\ue201","start_idx":4171,"end_idx":4191,"safe_urls":["https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text","https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com"],"refs":[],"alt":"([BioRxiv](https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"RareFold: Structure prediction and design of proteins with ...","url":"https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com","pub_date":null,"snippet":"8 Sept 2025 \u2014 Protein structure prediction and design have traditionally been limited to the 20 canonical amino acids. Expanding this space to include ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":10}],"hue":null,"attributions":null,"attribution":"BioRxiv"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search1\ue202turn0search7\ue202turn0search13\ue201","start_idx":4406,"end_idx":4452,"safe_urls":["https://github.com/gcorso/DiffDock","https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery","https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","https://www.nature.com/articles/s41586-024-07487-w","https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Accurate structure prediction of biomolecular interactions ...","url":"https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com","pub_date":null,"snippet":"by J Abramson \u00b7 2024 \u00b7 Cited by 9039 \u2014 Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.","attribution_segments":null,"supporting_websites":[{"title":"Implementation of DiffDock: Diffusion Steps, Twists, and ...","url":"https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","pub_date":null,"snippet":"Update February 2024: We have released DiffDock-L, a new version of DiffDock that provides a significant improvement in performance and generalization ...","attribution":"GitHub"},{"title":"NVIDIA BioNeMo Explained: Generative AI in Drug Discovery","url":"https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","pub_date":null,"snippet":"24 Oct 2025 \u2014 New models can be added or updated by the community; for example, NVIDIA's April 2025 release added MolMIM, a small-molecule generative ...","attribution":"IntuitionLabs"}],"refs":[{"turn_index":0,"ref_type":"search","ref_index":1},{"turn_index":0,"ref_type":"search","ref_index":7},{"turn_index":0,"ref_type":"search","ref_index":13}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search3\ue201","start_idx":4621,"end_idx":4640,"safe_urls":["https://www.nature.com/articles/s41586-025-09721-5","https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com"],"refs":[],"alt":"([Nature](https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Atomically accurate de novo design of antibodies with ...","url":"https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com","pub_date":null,"snippet":"by NR Bennett \u00b7 2025 \u00b7 Cited by 48 \u2014 Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network with yeast display screening enables the ...","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":3}],"hue":null,"attributions":null,"attribution":"Nature"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0search2\ue201","start_idx":4786,"end_idx":4805,"safe_urls":["https://www.science.org/doi/10.1126/science.ads0018","https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com"],"refs":[],"alt":"([Science](https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"Simulating 500 million years of evolution with a language ...","url":"https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com","pub_date":null,"snippet":"by T Hayes \u00b7 2025 \u00b7 Cited by 637 \u2014 We present ESM3, a frontier multimodal generative language model that reasons over the sequence, structure, and function of proteins.","attribution_segments":null,"supporting_websites":[],"refs":[{"turn_index":0,"ref_type":"search","ref_index":2}],"hue":null,"attributions":null,"attribution":"Science"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200cite\ue202turn0news81\ue202turn0search4\ue201","start_idx":5050,"end_idx":5081,"safe_urls":["https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/","https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com"],"refs":[],"alt":"([Financial Times](https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com))","prompt_text":null,"type":"grouped_webpages","items":[{"title":"OpenAI-backed Chai raises $70mn for AI-driven drug discovery","url":"https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","pub_date":1754497532.606,"snippet":"Chai Discovery, a two-year-old AI-driven drug discovery startup backed by OpenAI, has raised $70 million in funding, bringing its valuation to approximately $550 million. The round included investment from Menlo Ventures, DST Global Partners, and Yosemite, along with existing backers like Thrive Capital and OpenAI. Chai aims to revolutionize drug development by using artificial intelligence to design molecules and antibodies that can bind to proteins and potentially treat diseases, including those previously seen as \"undruggable.\"\n\nCo-founded by Joshua Meier and Jack Dent, the company\u2019s latest model, Chai-2, has shown significantly higher hit rates in early tests\u2014one in six proteins successfully targeted, compared to the traditional one in a thousand. Chai plans to commercialize its AI model through partnerships with pharmaceutical companies and has appointed former Pfizer CSO Mikael Dolsten to its board. Despite the inflow of capital into AI-driven biotech, industry results remain early-stage, with no AI-discovered drugs yet approved. Nonetheless, investors express optimism, seeing Chai\u2019s combination of deep AI capabilities and biological expertise as poised to disrupt the biopharma sector.","attribution_segments":null,"supporting_websites":[{"title":"Isomorphic Labs prepares to launch trials for AI-designed ...","url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com","pub_date":null,"snippet":"7 Jul 2025 \u2014 Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.","attribution":"Clinical Trials Arena"}],"refs":[{"turn_index":0,"ref_type":"news","ref_index":81},{"turn_index":0,"ref_type":"search","ref_index":4}],"hue":null,"attributions":null,"attribution":"Financial Times"}],"fallback_items":null,"status":"done","error":null,"style":null},{"matched_text":"\ue200navlist\ue202Fresh headlines to skim\ue202turn0news80,turn0news81,turn0news86\ue201","start_idx":5297,"end_idx":5366,"safe_urls":["https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/","https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com"],"refs":[{"turn_index":0,"ref_type":"news","ref_index":80},{"turn_index":0,"ref_type":"news","ref_index":81},{"turn_index":0,"ref_type":"news","ref_index":86}],"alt":"- [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com)\n- [Financial Times](https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com)\n- [New York Post](https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com)","prompt_text":"\nnavlist containing the following URLs:\n- [US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership](https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com)\n- [OpenAI-backed Chai raises $70mn for AI-driven drug discovery](https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com)\n- [Alphabet's Isomorphic Labs raises $600M in first funding round for AI drug business](https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com)\n","type":"nav_list","title":"Fresh headlines to skim","items":[{"title":"US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com","thumbnail_url":null,"pub_date":1760432893.0,"attribution":"Reuters"},{"title":"OpenAI-backed Chai raises $70mn for AI-driven drug discovery","url":"https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","thumbnail_url":null,"pub_date":1754497532.606,"attribution":"Financial Times"},{"title":"Alphabet's Isomorphic Labs raises $600M in first funding round for AI drug business","url":"https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","thumbnail_url":null,"pub_date":1743446583.0,"attribution":"New York Post"}],"user_time_zone":"Asia/Singapore"},{"matched_text":" ","start_idx":5366,"end_idx":5366,"safe_urls":[],"refs":[],"alt":"","prompt_text":null,"type":"sources_footnote","sources":[{"title":"Accurate structure prediction of biomolecular interactions ...","url":"https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com","attribution":"Nature"},{"title":"Simulating 500 million years of evolution with a language ...","url":"https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com","attribution":"Science"},{"title":"RareFold: Structure prediction and design of proteins with ...","url":"https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com","attribution":"BioRxiv"},{"title":"Implementation of DiffDock: Diffusion Steps, Twists, and ...","url":"https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","attribution":"GitHub"},{"title":"Alphabet's Isomorphic Labs raises $600M in first funding round for AI drug business","url":"https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","attribution":"New York Post"},{"title":"Generate:Biomedicines Provides Update on its Platform ...","url":"https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline?utm_source=chatgpt.com","attribution":"Generate:Biomedicines"},{"title":"NVIDIA GTC 2025 Highlights Foundation Models and AI ...","url":"https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com","attribution":"GEN"},{"title":"US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com","attribution":"Reuters"},{"title":"OpenAI-backed Chai raises $70mn for AI-driven drug discovery","url":"https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","attribution":"Financial Times"}],"has_images":false}],"safe_urls":["https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/","https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/?utm_source=chatgpt.com","https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/","https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/?utm_source=chatgpt.com","https://generatebiomedicines.com/","https://generatebiomedicines.com/?utm_source=chatgpt.com","https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline","https://generatebiomedicines.com/media-center/generatebiomedicines-provides-update-on-its-platform-and-pipeline?utm_source=chatgpt.com","https://github.com/gcorso/DiffDock","https://github.com/gcorso/DiffDock?utm_source=chatgpt.com","https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery","https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/","https://nypost.com/2025/03/31/business/alphabets-isomorphic-labs-raises-600m-for-ai-drug-business/?utm_source=chatgpt.com","https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text","https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2.full-text?utm_source=chatgpt.com","https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/","https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com","https://www.evolutionaryscale.ai/blog/esm3-release","https://www.evolutionaryscale.ai/blog/esm3-release?utm_source=chatgpt.com","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a","https://www.ft.com/content/eeaff7a2-acc8-4a79-a564-80debdcecc1a?utm_source=chatgpt.com","https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/","https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2025-highlights-foundation-models-and-ai-drug-discovery/?utm_source=chatgpt.com","https://www.nature.com/articles/d41586-024-02214-x","https://www.nature.com/articles/d41586-024-02214-x?utm_source=chatgpt.com","https://www.nature.com/articles/d41586-025-03546-y","https://www.nature.com/articles/d41586-025-03546-y?utm_source=chatgpt.com","https://www.nature.com/articles/s41586-024-07487-w","https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com","https://www.nature.com/articles/s41586-025-09721-5","https://www.nature.com/articles/s41586-025-09721-5?utm_source=chatgpt.com","https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/","https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/?utm_source=chatgpt.com","https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html","https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html?utm_source=chatgpt.com","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/","https://www.reuters.com/business/healthcare-pharmaceuticals/us-biotech-nabla-bio-japans-takeda-expand-ai-drug-design-partnership-2025-10-14/?utm_source=chatgpt.com","https://www.science.org/content/blog-post/computational-care","https://www.science.org/content/blog-post/computational-care?utm_source=chatgpt.com","https://www.science.org/doi/10.1126/science.ads0018","https://www.science.org/doi/10.1126/science.ads0018?utm_source=chatgpt.com"],"search_result_groups":[{"type":"search_result_group","domain":"clinicaltrialsarena.com","entries":[{"type":"search_result","url":"https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/?utm_source=chatgpt.com","title":"Isomorphic Labs prepares to launch trials for AI-designed ...","snippet":"7 Jul 2025 \u2014 Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":4},"pub_date":null,"attribution":"clinicaltrialsarena.com"}]},{"type":"search_result_group","domain":"nvidia.com","entries":[{"type":"search_result","url":"https://www.nvidia.com/en-sg/industries/healthcare-life-sciences/biopharma/?utm_source=chatgpt.com","title":"BioNeMo for Biopharma | Drug Discovery with Generative AI","snippet":"Accelerate drug discovery with NVIDIA BioNeMo for biopharma, a collection of frameworks, applications, generative AI solutions, and pretrained models.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":6},"pub_date":null,"attribution":"nvidia.com"},{"type":"search_result","url":"https://blogs.nvidia.com/blog/evolutionaryscale-esm3-generative-ai-nim-bionemo-h100/?utm_source=chatgpt.com","title":"EvolutionaryScale Debuts With ESM3 Generative AI Model ...","snippet":"25 Jun 2024 \u2014 ESM3 provides biologists and protein designers with a generative AI boost, helping improve their engineering and understanding of proteins.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":25},"pub_date":null,"attribution":"nvidia.com"},{"type":"search_result","url":"https://docs.nvidia.com/nim/bionemo/rfdiffusion/latest/overview.html?utm_source=chatgpt.com","title":"Overview \u2014 NVIDIA NIM for RFdiffusion","snippet":"RFdiffusion is a deep learning model for generating protein structures using a diffusion-based approach, and is part of NIMs for drug discovery.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":26},"pub_date":null,"attribution":"nvidia.com"},{"type":"search_result","url":"https://developer.nvidia.com/blog/tag/bionemo/?utm_source=chatgpt.com","title":"Tag: BioNeMo | NVIDIA Technical Blog","snippet":"Training Federated AI Models to Predict Protein Properties. Predicting where proteins are located inside a cell is critical in biology and drug discovery.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":29},"pub_date":null,"attribution":"nvidia.com"},{"type":"search_result","url":"https://docs.nvidia.com/nim/bionemo/diffdock/latest/release-notes.html?utm_source=chatgpt.com","title":"Release Notes \u2014 NVIDIA NIM for DiffDock","snippet":"Improved reporting on details with failed docking requests. Removed TritonServer ... Copyright \u00a9 2024-2025, NVIDIA Corporation. Last updated on Aug 27, 2025.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":30},"pub_date":null,"attribution":"nvidia.com"},{"type":"search_result","url":"https://developer.nvidia.com/blog/reasoning-through-molecular-synthetic-pathways-with-generative-ai/?utm_source=chatgpt.com","title":"Reasoning Through Molecular Synthetic Pathways with ...","snippet":"23 Sept 2025 \u2014 This post introduces ReaSyn, a generative model from NVIDIA designed for predicting molecular synthesis pathways that also addresses limitations ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":69},"pub_date":null,"attribution":"nvidia.com"}]},{"type":"search_result_group","domain":"biotechniques.com","entries":[{"type":"search_result","url":"https://www.biotechniques.com/drug-discovery-development/how-will-ai-first-drug-design-transform-human-health/?utm_source=chatgpt.com","title":"How will AI-first drug design transform human health?","snippet":"5 days ago \u2014 Find out how developments in AlphaFold 3, alongside new predictive models, are changing approaches to drug discovery and design.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":8},"pub_date":null,"attribution":"biotechniques.com"}]},{"type":"search_result_group","domain":"nature.com","entries":[{"type":"search_result","url":"https://www.nature.com/articles/d41586-024-02214-x?utm_source=chatgpt.com","title":"Ex-Meta scientists debut gigantic AI protein design model","snippet":"8 Jul 2024 \u2014 EvolutionaryScale's AI tool, called ESM3, is what's known as a protein language model. It was trained on more than 2.7 billion protein sequences ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":9},"pub_date":null,"attribution":"nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/s41594-024-01350-2?utm_source=chatgpt.com","title":"AlphaFold3 takes a step toward decoding molecular ...","snippet":"by R Roy \u00b7 2024 \u00b7 Cited by 68 \u2014 AlphaFold 3 represents a breakthrough in predicting the 3D structures of complexes directly from their sequences, offering insights into biomolecular ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":24},"pub_date":null,"attribution":"nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/d41586-024-03708-4?utm_source=chatgpt.com","title":"AI protein-prediction tool AlphaFold3 is now more open","snippet":"11 Nov 2024 \u2014 The code underlying the Nobel-prize-winning tool for modelling protein structures can now be downloaded by academics.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":64},"pub_date":null,"attribution":"nature.com"},{"type":"search_result","url":"https://www.nature.com/articles/s42004-025-01506-1?utm_source=chatgpt.com","title":"A Folding-Docking-Affinity framework for protein-ligand ...","snippet":"by MH Wu \u00b7 2025 \u00b7 Cited by 10 \u2014 Recent advancements in more innovative deep learning-based models, such as the updated versions of DiffDock, DiffDock-L, and DynamicBind, are ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":78},"pub_date":null,"attribution":"nature.com"}]},{"type":"search_result_group","domain":"isomorphiclabs.com","entries":[{"type":"search_result","url":"https://www.isomorphiclabs.com/?utm_source=chatgpt.com","title":"Isomorphic Labs: Reimagining Drug Discovery Process with AI","snippet":"Isomorphic Labs is building a future where frontier AI can help to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":11},"pub_date":null,"attribution":"isomorphiclabs.com"},{"type":"search_result","url":"https://www.isomorphiclabs.com/partnerships?utm_source=chatgpt.com","title":"Partnerships","snippet":"Reflecting the progress made in just over one year of working together, Iso and Novartis announced an expansion of our partnership in February 2025. The initial ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":59},"pub_date":null,"attribution":"isomorphiclabs.com"}]},{"type":"search_result_group","domain":"prnewswire.com","entries":[{"type":"search_result","url":"https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html?utm_source=chatgpt.com","title":"Generate:Biomedicines Provides Update on its Platform ...","snippet":"9 Jan 2025 \u2014 The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":12},"pub_date":null,"attribution":"prnewswire.com"},{"type":"search_result","url":"https://www.prnewswire.com/news-releases/generatebiomedicines-to-present-phase-1-results-for-ai-engineered-gb-0895-in-asthma-at-the-european-respiratory-society-international-congress-302566586.html?utm_source=chatgpt.com","title":"Generate:Biomedicines to Present Phase 1 Results for AI- ...","snippet":"25 Sept 2025 \u2014 The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":52},"pub_date":null,"attribution":"prnewswire.com"}]},{"type":"search_result_group","domain":"intuitionlabs.ai","entries":[{"type":"search_result","url":"https://intuitionlabs.ai/articles/nvidia-bionemo-drug-discovery?utm_source=chatgpt.com","title":"NVIDIA BioNeMo Explained: Generative AI in Drug Discovery","snippet":"24 Oct 2025 \u2014 New models can be added or updated by the community; for example, NVIDIA's April 2025 release added MolMIM, a small-molecule generative ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":13},"pub_date":null,"attribution":"intuitionlabs.ai"}]},{"type":"search_result_group","domain":"science.org","entries":[{"type":"search_result","url":"https://www.science.org/content/blog-post/computational-care?utm_source=chatgpt.com","title":"Computational Care","snippet":"6 Dec 2024 \u2014 Not only is DiffDock significantly more accurate than previous approaches to traditional docking benchmarks, thanks to its ability to reason at ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":14},"pub_date":null,"attribution":"science.org"}]},{"type":"search_result_group","domain":"merckgroup.com","entries":[{"type":"search_result","url":"https://www.merckgroup.com/en/news/protein-folding-hackathon-27-10-2025.html?utm_source=chatgpt.com","title":"Global Hackathon by Merck and Boltz for AI-Driven Protein ...","snippet":"27 Oct 2025 \u2014 A global hackathon by Merck and the Boltz-team on protein folding has set a new benchmark for open-source AI-driven innovation in drug ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":15},"pub_date":null,"attribution":"merckgroup.com"}]},{"type":"search_result_group","domain":"blog.google","entries":[{"type":"search_result","url":"https://blog.google/technology/ai/google-deepmind-isomorphic-alphafold-3-ai-model/?utm_source=chatgpt.com","title":"AlphaFold 3 predicts the structure and interactions of all ...","snippet":"8 May 2024 \u2014 AlphaFold 3 achieves unprecedented accuracy in predicting drug-like interactions, including the binding of proteins with ligands and antibodies ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":16},"pub_date":null,"attribution":"blog.google"}]},{"type":"search_result_group","domain":"evolutionaryscale.ai","entries":[{"type":"search_result","url":"https://www.evolutionaryscale.ai/blog/esm3-release?utm_source=chatgpt.com","title":"ESM3: Simulating 500 million years of evolution with a ...","snippet":"25 Jun 2024 \u2014 ESM3 is a tool for scientists. Our API and open model allow scientists to explore the frontiers of protein design and synthetic biology.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":17},"pub_date":null,"attribution":"evolutionaryscale.ai"}]},{"type":"search_result_group","domain":"sciencedirect.com","entries":[{"type":"search_result","url":"https://www.sciencedirect.com/science/article/pii/S0969212625003119?utm_source=chatgpt.com","title":"Review Code to complex: AI-driven de novo binder design","snippet":"by DR Fox \u00b7 2025 \u2014 Recent updates to RFdiffusion and RoseTTAFold2 have begun to incorporate atomic-level modeling of non-protein biomolecules, which could enable ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":18},"pub_date":null,"attribution":"sciencedirect.com"},{"type":"search_result","url":"https://www.sciencedirect.com/science/article/abs/pii/S0031699725075118?utm_source=chatgpt.com","title":"Leading AI-Driven Drug Discovery Platforms","snippet":"22 hours ago \u2014 We then provide an updated 2024\u20132025 perspective of new trial results, partnerships, platform enhancements, and strategic shifts for each ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":43},"pub_date":null,"attribution":"sciencedirect.com"},{"type":"search_result","url":"https://www.sciencedirect.com/science/article/pii/S2666675824001231?utm_source=chatgpt.com","title":"Drug development in the AI era: AlphaFold 3 is coming!","snippet":"by Y Shi \u00b7 2024 \u00b7 Cited by 16 \u2014 It will take about 12\u201315 years and cost about 2.5 billion US dollars from initial drug discovery to market in the conventional drug development way.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":72},"pub_date":null,"attribution":"sciencedirect.com"},{"type":"search_result","url":"https://www.sciencedirect.com/science/article/pii/S0959440X25000223?utm_source=chatgpt.com","title":"Foundation models of protein sequences: A brief overview","snippet":"by A Bjerregaard \u00b7 2025 \u00b7 Cited by 4 \u2014 ESM-3 uses functional annotations at both residue and sequence levels, derived from InterPro. Synthetic sequences from inverse folding increase the training ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":73},"pub_date":null,"attribution":"sciencedirect.com"}]},{"type":"search_result_group","domain":"fortune.com","entries":[{"type":"search_result","url":"https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials/?utm_source=chatgpt.com","title":"Isomorphic Labs has grand ambitions to 'solve all diseases ...","snippet":"6 Jul 2025 \u2014 Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":19},"pub_date":null,"attribution":"fortune.com"}]},{"type":"search_result_group","domain":"generatebiomedicines.com","entries":[{"type":"search_result","url":"https://generatebiomedicines.com/?utm_source=chatgpt.com","title":"Generate:Biomedicines | Home","snippet":"The Generate Platform can generate medicines on demand across multiple therapeutic modalities with unprecedented speed and success rates, representing a ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":20},"pub_date":null,"attribution":"generatebiomedicines.com"}]},{"type":"search_result_group","domain":"nih.gov","entries":[{"type":"search_result","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12406700/?utm_source=chatgpt.com","title":"Beyond rigid docking: deep learning approaches for fully ...","snippet":"by J Lee \u00b7 2025 \u2014 Additionally, new computational methods are continuously being developed and improved for accuracy, speed, and reliability [2]. Molecular ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":22},"pub_date":null,"attribution":"nih.gov"},{"type":"search_result","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12342994/?utm_source=chatgpt.com","title":"AlphaFold 3: an unprecedent opportunity for fundamental ...","snippet":"by Z Fang \u00b7 2025 \u00b7 Cited by 8 \u2014 With unprecedented accuracy, the AF3 model may successfully predict the structure and interactions of virtually all biomolecules, including proteins, ligands, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":32},"pub_date":null,"attribution":"nih.gov"},{"type":"search_result","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12467925/?utm_source=chatgpt.com","title":"The Role of AI-Driven De Novo Protein Design in the ...","snippet":"by G Zhang \u00b7 2025 \u2014 This architecture delivers breakthroughs in designing long-chain and novel proteins, outperforming established methods such as ProteinMPNN [102] ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":50},"pub_date":null,"attribution":"nih.gov"}]},{"type":"search_result_group","domain":"acs.org","entries":[{"type":"search_result","url":"https://cen.acs.org/pharmaceuticals/AI-based-protein-discovery-startstrikes/103/web/2025/10?utm_source=chatgpt.com","title":"AI-based protein discovery start-up strikes a second deal with ...","snippet":"14 Oct 2025 \u2014 Takeda Pharmaceuticals and Nabla Bio, a start-up focused on designing de novo proteins with artificial intelligence, have signed a second ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":23},"pub_date":null,"attribution":"acs.org"},{"type":"search_result","url":"https://pubs.acs.org/doi/10.1021/acs.jcim.5c00380?utm_source=chatgpt.com","title":"Integrating Machine Learning-Based Pose Sampling with ...","snippet":"by TNL Vu \u00b7 2025 \u00b7 Cited by 1 \u2014 In this study, we explore the integration of DiffDock-L, a leading ML-based pose sampling method, into VS workflows by combining it with the Vina, Gnina, and ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":54},"pub_date":null,"attribution":"acs.org"}]},{"type":"search_result_group","domain":"techinasia.com","entries":[{"type":"search_result","url":"https://www.techinasia.com/news/alphabets-ai-drug-firm-plans-first-human-trial?utm_source=chatgpt.com","title":"Alphabet's AI drug firm plans first human trial","snippet":"9 Jul 2025 \u2014 Isomorphic Labs, a UK-based subsidiary of Alphabet, is preparing for its first human clinical trial of a drug developed with AI.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":27},"pub_date":null,"attribution":"techinasia.com"}]},{"type":"search_result_group","domain":"biospace.com","entries":[{"type":"search_result","url":"https://www.biospace.com/press-releases/generate-biomedicines-announces-multi-target-collaboration-with-novartis-to-discover-and-develop-protein-therapeutics-with-generative-ai?utm_source=chatgpt.com","title":"Generate:Biomedicines Announces Multi-Target ...","snippet":"24 Sept 2024 \u2014 Our platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":28},"pub_date":null,"attribution":"biospace.com"}]},{"type":"search_result_group","domain":"astrazeneca.com","entries":[{"type":"search_result","url":"https://www.astrazeneca.com/content/astraz/what-science-can-do/topics/data-science-ai/mapdiff-edge-set-attention-ai-protein-design-breakthroughs.html?utm_source=chatgpt.com","title":"AI Drug Discovery: MapDiff & Edge Set Attention ...","snippet":"3 Oct 2025 \u2014 Our AI framework tackles the challenges of inverse protein folding through several key innovations: Guided design strategy: This novel ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":31},"pub_date":null,"attribution":"astrazeneca.com"}]},{"type":"search_result_group","domain":"github.com","entries":[{"type":"search_result","url":"https://github.com/evolutionaryscale/esm?utm_source=chatgpt.com","title":"evolutionaryscale/esm","snippet":"ESM3 is our flagship multimodal protein generative model, and can be used for generation and prediction tasks. ESM C is our best protein representation learning ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":33},"pub_date":null,"attribution":"github.com"},{"type":"search_result","url":"https://github.com/RosettaCommons/RFdiffusion?utm_source=chatgpt.com","title":"RosettaCommons/RFdiffusion: Code for running ...","snippet":"3 Apr 2023 \u2014 We have recently published the RFpeptides protocol for using RFdiffusion to design macrocyclic peptides that bind target proteins with atomic ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":58},"pub_date":null,"attribution":"github.com"}]},{"type":"search_result_group","domain":"uw.edu","entries":[{"type":"search_result","url":"https://www.ipd.uw.edu/2024/11/introducing-rfpeptides-ai-for-cyclic-peptide-design/?utm_source=chatgpt.com","title":"Introducing RFpeptides - Institute for Protein Design","snippet":"25 Nov 2024 \u2014 RFpeptides is an AI tool that designs ring-shaped bioactive peptides with precise 3D structures, using deep learning to bind to disease-related ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":34},"pub_date":null,"attribution":"uw.edu"}]},{"type":"search_result_group","domain":"yahoo.com","entries":[{"type":"search_result","url":"https://finance.yahoo.com/news/isomorphic-labs-prepares-launch-trials-112706321.html?utm_source=chatgpt.com","title":"Isomorphic Labs prepares to launch trials for AI-designed ...","snippet":"7 Jul 2025 \u2014 Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":35},"pub_date":null,"attribution":"yahoo.com"},{"type":"search_result","url":"https://finance.yahoo.com/news/samsung-invests-generate-biomedicines-advance-050900199.html?utm_source=chatgpt.com","title":"Samsung invests in Generate: Biomedicines to advance AI- ...","snippet":"17 Dec 2024 \u2014 The company applies AI-based optimization and de novo generation to discover and design novel protein therapeutics, and has a robust pipeline of ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":36},"pub_date":null,"attribution":"yahoo.com"}]},{"type":"search_result_group","domain":"news-medical.net","entries":[{"type":"search_result","url":"https://www.news-medical.net/news/20250320/Sapio-Sciences-makes-AI-Native-drug-discovery-seamless-with-NVIDIA-BioNeMo.aspx?utm_source=chatgpt.com","title":"Streamline drug discovery: Sapio integrates NVIDIA ...","snippet":"20 Mar 2025 \u2014 With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":37},"pub_date":null,"attribution":"news-medical.net"},{"type":"search_result","url":"https://www.news-medical.net/news/20251010/New-AI-system-revolutionizes-drug-design-and-vaccine-development.aspx?utm_source=chatgpt.com","title":"New AI system revolutionizes drug design and vaccine ...","snippet":"10 Oct 2025 \u2014 In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system capable of predicting the 3D structures and ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":39},"pub_date":null,"attribution":"news-medical.net"}]},{"type":"search_result_group","domain":"biorxiv.org","entries":[{"type":"search_result","url":"https://www.biorxiv.org/content/10.1101/2025.06.02.657461v1.full-text?utm_source=chatgpt.com","title":"DiffDock-Glide: a hybrid physics-based and data-driven ...","snippet":"We develop a hybrid model called DiffDock-Glide which addresses some shortcomings of deep learning docking methods.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":38},"pub_date":null,"attribution":"biorxiv.org"}]},{"type":"search_result_group","domain":"alphafoldserver.com","entries":[{"type":"search_result","url":"https://alphafoldserver.com/?utm_source=chatgpt.com","title":"AlphaFold Server","snippet":"AlphaFold Server \u2013 powered by AlphaFold 3 \u2013 provides accurate structure predictions for how proteins interact with other molecules, like DNA, RNA and more.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":40},"pub_date":null,"attribution":"alphafoldserver.com"}]},{"type":"search_result_group","domain":"fmai-hub.com","entries":[{"type":"search_result","url":"https://www.fmai-hub.com/esm3-a-new-frontier-for-advanced-protein-design/?utm_source=chatgpt.com","title":"ESM3 | A New Frontier for Advanced Protein Design","snippet":"27 Jun 2024 \u2014 A biotech startup from Meta has announced a revolutionary generative AI model called ESM3 capable of designing entirely new proteins.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":41},"pub_date":null,"attribution":"fmai-hub.com"}]},{"type":"search_result_group","domain":"3ds.com","entries":[{"type":"search_result","url":"https://blog.3ds.com/brands/biovia/ai-driven-protein-binder-design/?utm_source=chatgpt.com","title":"AI-Driven Protein Binder Design - 3DS Blog - Dassault Syst\u00e8mes","snippet":"10 Jun 2025 \u2014 AI, using RFdiffusion, refines protein structures from 'noise' to design binders. This involves a multi-step workflow including scaffold ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":42},"pub_date":null,"attribution":"3ds.com"}]},{"type":"search_result_group","domain":"nasdaq.com","entries":[{"type":"search_result","url":"https://www.nasdaq.com/press-release/generate-biomedicines-announces-multi-target-collaboration-novartis-discover-and?utm_source=chatgpt.com","title":"Generate:Biomedicines Announces Multi-Target ...","snippet":"24 Sept 2024 \u2014 This approach creates never-before-seen therapeutic molecules targeting specific biological processes involved in disease that can be modulated ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":44},"pub_date":null,"attribution":"nasdaq.com"}]},{"type":"search_result_group","domain":"nebius.com","entries":[{"type":"search_result","url":"https://nebius.com/blog/posts/powering-next-gen-biotech-research-with-nvidia?utm_source=chatgpt.com","title":"From genome analysis to quantum chemistry","snippet":"25 Jun 2025 \u2014 With access to 16 NVIDIA H200 GPUs and NVIDIA BioNeMo, Simulacra AI is developing a new class of generative models for chemistry \u2014 systems ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":45},"pub_date":null,"attribution":"nebius.com"}]},{"type":"search_result_group","domain":"310.ai","entries":[{"type":"search_result","url":"https://310.ai/blog/diffdock-but-better?utm_source=chatgpt.com","title":"DiffDock, but better","snippet":"18 Apr 2024 \u2014 The latest version of DiffDock, DiffDock-L (Corso et al. 2024), improves accuracy by up to 50% in blind docking compared to its predecessor and other tools.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":46},"pub_date":null,"attribution":"310.ai"}]},{"type":"search_result_group","domain":"blackthorn.ai","entries":[{"type":"search_result","url":"https://blackthorn.ai/blog/ai-in-biotech-trends-discoveries-and-game-changing-technologies/?utm_source=chatgpt.com","title":"AI in Biotech: 2025 Trends, Discoveries, and Game-Changing ...","snippet":"1 Sept 2025 \u2014 By 2025, the share of AI-discovered drugs is expected to reach 30% (World Economic Forum). AI can accelerate workflows and decrease the cost of ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":47},"pub_date":null,"attribution":"blackthorn.ai"}]},{"type":"search_result_group","domain":"researchgate.net","entries":[{"type":"search_result","url":"https://www.researchgate.net/publication/380445200_Accurate_structure_prediction_of_biomolecular_interactions_with_AlphaFold_3?utm_source=chatgpt.com","title":"(PDF) Accurate structure prediction of biomolecular ...","snippet":"8 May 2024 \u2014 Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":48},"pub_date":null,"attribution":"researchgate.net"}]},{"type":"search_result_group","domain":"livescience.com","entries":[{"type":"search_result","url":"https://www.livescience.com/technology/artificial-intelligence/new-glowing-molecule-invented-by-ai-would-have-taken-500-million-years-to-evolve-in-nature-scientists-say?utm_source=chatgpt.com","title":"New glowing molecule, invented by AI, would have taken ...","snippet":"28 Jan 2025 \u2014 This allows scientists to easily track proteins and cellular processes. Rives noted that ESM3's capabilities can accelerate a wide range of ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":49},"pub_date":null,"attribution":"livescience.com"}]},{"type":"search_result_group","domain":"medcloudinsider.com","entries":[{"type":"search_result","url":"https://medcloudinsider.com/articles/2025/07/16/isomorphic-preps-first-human-trials-for-ai-designed-drugs.aspx?utm_source=chatgpt.com","title":"Alphabet's Isomorphic Labs Preps First Human Trials for AI ...","snippet":"16 Jul 2025 \u2014 Alphabet's Isomorphic Labs says it's nearly ready to begin clinical trials on drugs designed entirely with artificial intelligence.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":51},"pub_date":null,"attribution":"medcloudinsider.com"}]},{"type":"search_result_group","domain":"lenovo.com","entries":[{"type":"search_result","url":"https://techtoday.lenovo.com/sites/default/files/2025-05/Drug%20Discovery%20White%20Paper.pdf?utm_source=chatgpt.com","title":"Accelerate AI for drug discovery","snippet":"NVIDIA BioNeMo \u2014 included with NVIDIA AI Enterprise \u2014 is a platform that accelerates and simplifies the building, customization, and deployment of AI models ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":53},"pub_date":null,"attribution":"lenovo.com"}]},{"type":"search_result_group","domain":"pelagobio.com","entries":[{"type":"search_result","url":"https://www.pelagobio.com/cetsa-drug-discovery-resources/blog/drug-discovery-trends-2025/?utm_source=chatgpt.com","title":"Top 5 Drug Discovery Trends 2025 Driving Breakthroughs","snippet":"Explore the top 5 Drug Discovery Trends 2025\u2014from AI to CETSA\u00ae\u2014driving faster R&D, smarter decisions, and better-targeted drug programs.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":55},"pub_date":null,"attribution":"pelagobio.com"}]},{"type":"search_result_group","domain":"mdpi.com","entries":[{"type":"search_result","url":"https://www.mdpi.com/1422-0067/26/8/3671?utm_source=chatgpt.com","title":"AlphaFold3: An Overview of Applications and Performance ...","snippet":"by MG Krokidis \u00b7 2025 \u00b7 Cited by 36 \u2014 AlphaFold's success in accurately predicting protein structures from amino acid sequences has revolutionized various fields, from drug discovery to disease ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":56},"pub_date":null,"attribution":"mdpi.com"}]},{"type":"search_result_group","domain":"dental-tribune.com","entries":[{"type":"search_result","url":"https://in.dental-tribune.com/news/esm3-accelerating-protein-evolution-with-ai/?utm_source=chatgpt.com","title":"ESM3: Accelerating protein evolution with AI","snippet":"1 Feb 2025 \u2014 ESM3 is a frontier AI model that can design new functional proteins\u2014like a novel fluorescent one\u2014comparable to half a billion years of natural ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":57},"pub_date":null,"attribution":"dental-tribune.com"}]},{"type":"search_result_group","domain":"mvp.vc","entries":[{"type":"search_result","url":"https://www.mvp.vc/company-initations/initiation-report-generate-biomedicines---pioneering-ai-powered-drug-discovery?utm_source=chatgpt.com","title":"Generate:Biomedicines \u2013 Pioneering AI-Powered Drug ...","snippet":"11 Jul 2024 \u2014 The platform's ability to produce over 42,000 proteins, all of which have been built and tested, underscores its capacity for high-throughput, ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":60},"pub_date":null,"attribution":"mvp.vc"}]},{"type":"search_result_group","domain":"medium.com","entries":[{"type":"search_result","url":"https://medium.com/sprintome/nvidia-gtc-2025-expert-look-at-foundation-models-in-biology-and-drug-discovery-efd7a5c5e9e6?utm_source=chatgpt.com","title":"AI Drug Discovery | Foundation Models @ GTC 2025","snippet":"As emphasized at GTC, NVIDIA's BioNeMo platform serves as a cornerstone for these advances, offering optimized performance for biological and ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":61},"pub_date":null,"attribution":"medium.com"}]},{"type":"search_result_group","domain":"thequantuminsider.com","entries":[{"type":"search_result","url":"https://thequantuminsider.com/2025/09/29/scisparc-plans-to-use-quantum-computers-to-model-3d-proteins-for-ai-drug-discovery/?utm_source=chatgpt.com","title":"SciSparc Plans to Use Quantum Computers to Model 3D ...","snippet":"29 Sept 2025 \u2014 SciSparc Plans to Use Quantum Computers to Model 3D Proteins For AI Drug Discovery \u00b7 accurately predict how proteins fold into their 3D shapes; ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":63},"pub_date":null,"attribution":"thequantuminsider.com"}]},{"type":"search_result_group","domain":"synbiobeta.com","entries":[{"type":"search_result","url":"https://www.synbiobeta.com/read/evolutionaryscale-raises-142m-and-unveils-ai-model-esm3-to-transform-biology?utm_source=chatgpt.com","title":"EvolutionaryScale Raises $142M and Unveils AI Model ...","snippet":"1 Jul 2024 \u2014 The ESM3 model represents a major leap in generative AI, enabling scientists to interactively prompt the creation of proteins. This advancement ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":65},"pub_date":null,"attribution":"synbiobeta.com"}]},{"type":"search_result_group","domain":"cell.com","entries":[{"type":"search_result","url":"https://www.cell.com/structure/pdf/S0969-2126%2825%2900311-9.pdf?utm_source=chatgpt.com","title":"Code to complex: AI-driven de novo binder design","snippet":"by DR Fox \u00b7 2025 \u2014 Modern frameworks: Diffusion models and current practice. The introduction of generative diffusion models has reshaped the landscape of de novo protein design.","ref_id":{"turn_index":0,"ref_type":"search","ref_index":66},"pub_date":null,"attribution":"cell.com"}]},{"type":"search_result_group","domain":"labiotech.eu","entries":[{"type":"search_result","url":"https://www.labiotech.eu/interview/generate-biomedicines-ai-drug-discovery/?utm_source=chatgpt.com","title":"Generate Biomedicines: boosting drug discovery with AI","snippet":"12 Oct 2022 \u2014 Generate uses machine learning (ML) and other computational tools to design protein drugs. To fuel the calculations, the company uses a ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":68},"pub_date":null,"attribution":"labiotech.eu"}]},{"type":"search_result_group","domain":"acm.org","entries":[{"type":"search_result","url":"https://dl.acm.org/doi/10.1145/3716368.3735212?utm_source=chatgpt.com","title":"DiffDock-FPGA: A Hardware Accelerator for Molecular ...","snippet":"by C Zhang \u00b7 2025 \u2014 For instance, by formulating docking as a generative problem, DiffDock achieves significant improvements in both accuracy and speed compared ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":70},"pub_date":null,"attribution":"acm.org"}]},{"type":"search_result_group","domain":"stanford.edu","entries":[{"type":"search_result","url":"https://hai.stanford.edu/ai-index/2025-ai-index-report/science-and-medicine?utm_source=chatgpt.com","title":"Science and Medicine | The 2025 AI Index Report | Stanford HAI","snippet":"Science and Medicine \u00b7 1. Bigger and better protein sequencing models emerge. \u00b7 2. AI continues to drive rapid advances in scientific discovery. \u00b7 3. The clinical ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":71},"pub_date":null,"attribution":"stanford.edu"}]},{"type":"search_result_group","domain":"nanohelix.ai","entries":[{"type":"search_result","url":"https://nanohelix.ai/blog/ai-protein-design-guide-2025?utm_source=chatgpt.com","title":"2025 Guide to AI-Driven Protein Design & Machine Learning ...","snippet":"1 Jul 2025 \u2014 This 2025 guide to AI-driven protein design and structural biology summarizes breakthroughs from the last six months (January\u2013June 2025)","ref_id":{"turn_index":0,"ref_type":"search","ref_index":74},"pub_date":null,"attribution":"nanohelix.ai"}]},{"type":"search_result_group","domain":"airstreet.com","entries":[{"type":"search_result","url":"https://press.airstreet.com/p/max-jaderberg-isomorphic-labs-2025?utm_source=chatgpt.com","title":"From move 37 to drug design - Air Street Press","snippet":"22 Jul 2025 \u2014 With over $600 million raised in its first external funding round, Isomorphic Labs is gearing up for a new chapter. The company is scaling its ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":75},"pub_date":null,"attribution":"airstreet.com"}]},{"type":"search_result_group","domain":"forgeglobal.com","entries":[{"type":"search_result","url":"https://forgeglobal.com/generate-biomedicines_stock/?utm_source=chatgpt.com","title":"Invest and Sell Generate:Biomedicines Stock","snippet":"15 Jul 2025 \u2014 The open-source software can help develop novel protein molecules with therapeutic properties, potentially speeding up protein design ...","ref_id":{"turn_index":0,"ref_type":"search","ref_index":76},"pub_date":null,"attribution":"forgeglobal.com"}]}],"citations":[],"model_slug":"gpt-5-thinking","request_id":"95554bee-a173-4bc8-bb20-989249263a3b","message_type":"next","default_model_slug":"gpt-5","parent_id":"f4713fd8-5a88-4ae6-8165-567cf16e90fa","turn_exchange_id":"5dc7775e-0dc5-4441-a59a-089c3129cae7","timestamp_":"absolute","can_save":true},"recipient":"all","channel":"final"},"parent":"f4713fd8-5a88-4ae6-8165-567cf16e90fa","children":[]}}}